Allergies News and Research

Latest Allergies News and Research

New class of compounds can stop the reproduction of coronavirus

A human genetic mechanism hijacked by SARS-CoV-2, the coronavirus behind the COVID-19 pandemic, to help it spread also makes it vulnerable to a new class of drug candidates, a new study finds.

24 Jun 2021

NIH begins study to evaluate how pregnant, postpartum people react to COVID-19 vaccines

A new observational study has begun to evaluate the immune responses generated by COVID-19 vaccines administered to pregnant or postpartum people.

23 Jun 2021

Airborne pollen grains facilitate spread of COVID-19 by carrying SARS-CoV-2 particles

Computer models simulating the movement of pollen grains from trees in crowded areas could accelerate the spread of COVID-19.

23 Jun 2021

New study enrolls young adults to evaluate SARS-CoV-2 infection

The Prevent COVID U study, which launched in late March 2021 to evaluate SARS-CoV-2 infection and transmission among university students vaccinated with the Moderna COVID-19 Vaccine, has expanded beyond the university setting to enroll young adults ages 18 through 29 years and will now also include people in this age group who choose not to receive a vaccine.

23 Jun 2021

Researchers investigate how pollen facilitates the spread of COVID-19 virus

Most models explaining how viruses are transmitted focus on viral particles escaping one person to infect a nearby person. A study on the role of microscopic particles in how viruses are transmitted suggests pollen is nothing to sneeze at.

22 Jun 2021

New universal vaccine protects mice against COVID-19 and other coronaviruses

Scientists at the University of North Carolina Gillings School of Global Public Health have developed a universal vaccine that protected mice not just against COVID-19 but also other coronaviruses and triggered the immune system to fight off a dangerous variant.

22 Jun 2021

Engineering nanobodies to fight against the SARS-CoV-2 virus

Scientists are pursuing a new strategy in the protracted fight against the SARS-CoV-2 virus by engineering nanobodies that can neutralize virus variants in two different ways.

22 Jun 2021

Study: Immune responses may develop against other proteins produced by SARS-CoV-2

All coronaviruses produce four primary structural proteins and multiple nonstructural proteins. However, the majority of antibody-based SARS-CoV-2 research has focused on the spike and nucleocapsid proteins.

22 Jun 2021

Texas Biomed scientists receive $1 million NIH funding for Ebola research

Scientists have a general idea of how viruses invade and spread in the body, but the precise mechanisms are actually not well understood, especially when it comes to Ebola virus.

18 Jun 2021

Previous SARS-CoV-2 infection, vaccines provide protection against gamma variant, study finds

In early January 2021, travelers returning to Tokyo, Japan, from Amazonas, Brazil, were screened for COVID-19 at the airport. A few days later, the National Institute of Infectious Disease of Japan announced that the travelers had returned with a new variant of the SARS-CoV-2 virus.

18 Jun 2021

FDA approves antihistamine nasal spray for over-the-counter use

The U.S. Food and Drug Administration today approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch.

17 Jun 2021

Antibody combination REGEN-COV prevents symptomatic disease following SARS-CoV-2 infection

Researchers in the United States have demonstrated the effectiveness of early treatment with REGEN-COV™ at preventing symptomatic disease among people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

17 Jun 2021

Researchers prepare for next coronavirus pandemic

Scientists are already preparing for a possible next coronavirus pandemic to strike, keeping with the seven-year pattern since 2004.

17 Jun 2021

New study may lead to more effective and powerful COVID-19 vaccines

A new study looking at the way human cells activate the immune system in response to SARS-CoV-2 infection could open the door to even more effective and powerful vaccines against the coronavirus and its rapidly emerging variants keeping the global pandemic smoldering.

17 Jun 2021

Two vaccines elicit durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical study

A group of scientists led by researchers at the University of North Carolina at Chapel Hill, Weill Cornell Medicine and NewYork-Presbyterian reported that the Moderna mRNA vaccine and a protein-based vaccine candidate elicited durable neutralizing antibody responses to SARS-CoV-2 in pre-clinical research. There were no adverse effects.

16 Jun 2021

COVID-19 Vaccine DSMB can serve as model for future situations

Clinical evaluation of three COVID-19 vaccine candidates in 2020-21 during a worldwide pandemic that killed or sickened millions was unprecedented in terms of urgency and scope.

16 Jun 2021

Researchers identify specific cells and proteins that control the sneeze reflex

A tickle in the nose can help trigger a sneeze, expelling irritants and disease-causing pathogens. But the cellular pathways that control the sneeze reflex go far beyond the sinuses and have been poorly understood.

16 Jun 2021

UCSF launches new initiative to propel the development of living therapeutics

UC San Francisco is launching a new initiative to propel the development of living therapeutics - a category of treatments broadly defined as human and microbial living cells that are selected, modified, or engineered to treat or cure disease - and bring them quickly to patients.

14 Jun 2021

HEPA air purifier can significantly reduce airborne COVID-19 particles

As COVID-19 restrictions ease nationwide and more people host indoor gatherings, investing in a high efficiency particulate air (HEPA) purifier might not be a bad idea, says a University of Cincinnati College of Medicine researcher.

11 Jun 2021

ACTG launches phase 1 HIV cure study evaluating two promising therapies

The AIDS Clinical Trials Group, the largest global HIV research network, today announced the launch of A5386, a phase 1 HIV cure study evaluating two promising therapies.

10 Jun 2021